SB 258719

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT₇ receptor partial inverse agonist, and was the first such ligand identified for 5-HT₇. Its use in research has mainly been in demonstrating the potential use for 5-HT₇ agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT₇ agonists across several different testing models.